Great Lakes Advisors LLC Decreases Stock Holdings in AbbVie Inc. $ABBV

Great Lakes Advisors LLC decreased its stake in shares of AbbVie Inc. (NYSE:ABBV) by 1.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 604,409 shares of the company’s stock after selling 6,773 shares during the period. AbbVie comprises 1.2% of Great Lakes Advisors LLC’s portfolio, making the stock its 18th largest holding. Great Lakes Advisors LLC’s holdings in AbbVie were worth $139,946,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the stock. Evolution Wealth Management Inc. purchased a new position in shares of AbbVie in the 2nd quarter worth $26,000. Spurstone Advisory Services LLC purchased a new stake in AbbVie during the second quarter valued at $28,000. Financial Gravity Companies Inc. bought a new position in AbbVie in the second quarter valued at about $36,000. Delos Wealth Advisors LLC purchased a new position in AbbVie in the second quarter worth about $39,000. Finally, Bear Mountain Capital Inc. grew its stake in shares of AbbVie by 480.6% during the 2nd quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock valued at $40,000 after purchasing an additional 173 shares during the period. Institutional investors own 70.23% of the company’s stock.

Analyst Upgrades and Downgrades

ABBV has been the topic of several recent research reports. DZ Bank cut shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price objective on the stock. in a research note on Tuesday, November 4th. Berenberg Bank set a $275.00 price target on shares of AbbVie in a research report on Tuesday, January 20th. UBS Group reissued a “neutral” rating on shares of AbbVie in a research report on Tuesday, January 13th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $223.00 target price on shares of AbbVie in a report on Wednesday. Finally, Bank of America lifted their target price on AbbVie from $220.00 to $251.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $249.37.

AbbVie Price Performance

Shares of ABBV stock opened at $218.99 on Thursday. AbbVie Inc. has a one year low of $164.39 and a one year high of $244.81. The company’s fifty day moving average price is $224.85 and its 200-day moving average price is $218.01. The company has a market capitalization of $387.04 billion, a price-to-earnings ratio of 165.90, a PEG ratio of 0.92 and a beta of 0.36.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. The business had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.AbbVie’s revenue for the quarter was up 9.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Equities research analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be paid a dividend of $1.73 per share. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date of this dividend is Friday, January 16th. This represents a $6.92 annualized dividend and a yield of 3.2%. AbbVie’s dividend payout ratio is 524.24%.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Retrospective look: an analysis of why AbbVie outperformed in 2025 highlights management’s handling of blockbuster patent cliffs and portfolio transitions, supporting investor confidence in AbbVie’s strategy and cash returns. Why AbbVie Stock Trounced the Market in 2025
• Positive Sentiment: Berenberg raised its price target to $275 (from $270) and kept a Buy rating, citing momentum for Skyrizi and Rinvoq — a bullish signal from an institutional analyst that can support upside. Berenberg Grows More Confident in AbbVie
• Positive Sentiment: AbbVie and Novartis announced multi‑billion dollar licensing arrangements for oncology and Alzheimer’s treatments — a pipeline/collaboration boost that could add long-term revenue optionality. AbbVie and Novartis Announce Billion Dollar Licensing Deals
• Positive Sentiment: Clinical/dev updates: coverage discusses a bispecific trial win and AbbVie’s R&D commitments that could strengthen the growth narrative if results translate to approvals. Does AbbVie’s Bispecific Trial Win…
• Positive Sentiment: AbbVie completed a Phase 1 study for an on‑body injector to deliver risankizumab — operational progress that could improve dosing convenience and commercial uptake. AbbVie Advances Risankizumab Delivery
• Positive Sentiment: Allergan Aesthetics released pooled Phase 3 and Phase 4 data across injectables at IMCAS, underscoring strength in the aesthetics business line. Allergan Aesthetics Unveils New Data
• Positive Sentiment: On-air analyst support: a CNBC guest recommended staying long AbbVie, a short-term endorsement that can help sentiment. AbbVie on CNBC’s ‘Final Trades’
• Neutral Sentiment: Options activity: commentary notes unusual options movement, worth watching for short-term volatility but not definitive direction. Is the Options Market Predicting a Spike?
• Neutral Sentiment: Insider/holder note: a small asset manager disclosed a modest stake increase — a minor vote of confidence but immaterial to market cap. Belpointe Asset Management Increases Stake
• Neutral Sentiment: Corporate philanthropy: the AbbVie Foundation opened applications for a health equity accelerator — positive PR but unlikely to move the stock. AbbVie Foundation Health Equity Accelerator
• Negative Sentiment: Policy risk: CMS named several AbbVie drugs for the third cycle of Medicare Drug Price Negotiations — a direct potential headwind to pricing and margins if negotiations lower reimbursement. US Medicare names Eli Lilly, Pfizer and AbbVie drugs
• Negative Sentiment: Earnings outlook: a Zacks preview said AbbVie lacks the setup for a clear earnings beat next week — a factor that can pressure near-term multiple and stock momentum. AbbVie Reports Next Week
• Negative Sentiment: Analyst change: Citigroup trimmed its price target to $230 and moved to Neutral, signaling less near-term upside from analyst coverage. Citigroup Lowers Price Target

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.